NCT02135133 2026-03-17
A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL
Dana-Farber Cancer Institute
Phase 2 Completed
Clinical Trials
28 trialsNCT01496976 2025-12-19
Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT01258933 2025-10-01
Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT01361711 2025-05-23
Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia
Northwestern University
Phase 2 Active not recruiting
NCT01352312 2025-04-29
Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma
Thomas Jefferson University
Phase 1 Terminated
NCT02388048 2025-01-29
Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic Leukemia
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 2 Completed
NCT01243190 2024-09-19
Ofatumumab for High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03280160 2022-09-16
Protocol GELLC-7: Ibrutinib Followed by Ibrutinib Consolidation in Combination With Ofatumumab
PETHEMA Foundation
Phase 2 Unknown
NCT01455051 2022-05-06
Ofatumumab as Part of Reduced Intensity Conditioning (RIC) Regimen for Patients With High Risk Chronic Lymphocytic Leukemia (CLL) Undergoing Allogeneic Hematopoietic Cell Transplantation
Grupo Espanol de trasplantes hematopoyeticos y terapia celular
Phase 2 Completed
NCT01444716 2021-07-26
Ofatumumab as Front-Line Therapy in Treating Elderly Participants With Chronic Lymphocytic Leukemia
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01716208 2021-05-11
Ofatumumab and Fresh Frozen Plasma in Patients With Chronic Lymphocytic Lymphoma
University of California, Davis
Phase 2 Completed
NCT01497496 2021-04-27
Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT02689141 2020-06-11
Sequential Regimen of Bendamustin-Debulking Followed by Ofatumumab and Ibrutinib in CLL Patients (CLL2-BIO)
German CLL Study Group
Phase 2 Completed
NCT01532700 2019-09-24
An Open-Label Phase 2 Study of Ofatumumab (Arzerra) in Combination With Oral GSK2110183 in the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL)
University Health Network, Toronto
Phase 2 Completed
NCT02614508 2019-09-03
Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Emory University
Phase 1 Terminated
NCT01002755 2019-05-07
Lenalidomide and Ofatumumab in Treating Participants With Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01024010 2018-09-18
Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Mayo Clinic
Phase 2 Completed
NCT01191190 2018-05-08
CRC027
University of California, San Diego
Phase 2 Completed
NCT01239394 2017-10-18
Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma
Massachusetts General Hospital
Phase 2 Completed
NCT01848145 2017-06-06
Rapid Infusion of Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia
SCRI Development Innovations, LLC
Phase 2 Completed
NCT01681563 2016-12-28
Trial of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) in Older Patients With Chronic Lymphocytic Leukemia
Niguarda Hospital
Phase 2 Completed
NCT01113632 2016-09-20
Ofatumumab for Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
SCRI Development Innovations, LLC
Phase 2 Completed
NCT01809847 2016-09-19
Ofatumumab Induction and Maintenance in Elderly Patients With Poor Risk CLL in the Context of Allogeneic Transplantation
Technische Universität Dresden
Phase 2 Completed
NCT01010568 2015-12-15
Ofatumumab and Bendamustine for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Georgetown University
Phase 2 Terminated
NCT01123356 2015-12-03
Treatment of Chronic Lymphocytic Leukemia in Patients Previously Exposed to Rituximab
Medical University of South Carolina
Phase 2 Completed
NCT01310101 2015-02-03
Ofatumumab Added to Dexamethasone in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia
Brno University Hospital
Phase 2 Completed
NCT01125787 2011-07-20
Clinical Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia With a Combination of Bendamustine and Ofatumumab
Nevada Cancer Institute
Phase 2 Terminated
NCT01131247 2011-07-20
PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & Ofatumumab
Nevada Cancer Institute
Phase 2 Withdrawn